How often do patients with psoriatic arthritis and abdominal aortic atherosclerosis experience myalgias when treated with a moderate- to high-intensity statin, given a zero coronary calcium score?

Frequency of Statin-Associated Myalgias

Statin-associated muscle symptoms (myalgias with normal CK) occur in 1-5% of patients in randomized controlled trials, but are reported in 5-20% of patients in observational studies and real-world clinical practice 1.

Understanding the Discrepancy Between Trial and Real-World Data

The substantial gap between RCT rates (1-5%) and observational rates (5-20%) reflects important clinical realities 1:

• Randomized trials systematically exclude patients with prior statin intolerance and use strict protocols that may not reflect typical practice
• Real-world settings capture subjective myalgias that may or may not be causally related to statins
• The nocebo effect plays a significant role—many symptoms attributed to statins resolve with rechallenge or occur at similar rates with placebo

Context-Specific Risk in Your Patient Population

For a patient with psoriatic arthritis and abdominal aortic atherosclerosis, several factors warrant consideration:

Increased Risk Factors Present 2:

• Rheumatologic disorder (psoriatic arthritis itself increases myalgia risk)
• Multisystem disease (atherosclerotic burden)
• Potential for multiple medications (common in PsA management)

Important Caveat About Baseline Assessment

Before initiating statin therapy, obtain a detailed history of current muscle symptoms to establish baseline 3. This is critical because:

• Psoriatic arthritis patients may have pre-existing musculoskeletal symptoms
• Distinguishing statin-related myalgias from disease-related symptoms becomes nearly impossible without baseline documentation
• This baseline prevents unnecessary statin discontinuation

Clinical Management Algorithm

If Myalgias Develop:

Mild-to-moderate symptoms 3:

1. Temporarily discontinue the statin
2. Evaluate alternative causes: hypothyroidism, vitamin D deficiency, worsening PsA activity, steroid myopathy
3. Check CK level (compare to baseline if available)
4. Once symptoms resolve, rechallenge with same or lower dose to establish causality
5. If symptoms recur, switch to a different statin at lower dose
6. Gradually uptitrate as tolerated

Severe symptoms or weakness 3:

1. Immediately discontinue statin
2. Urgent evaluation for rhabdomyolysis: CK, creatinine, urinalysis for myoglobinuria
3. Check thyroid function

Key Clinical Pitfalls

• Do NOT routinely monitor CK in asymptomatic patients—it adds no value 1
• Do NOT assume all muscle symptoms are statin-related in PsA patients—rule out disease flare, vitamin D deficiency, hypothyroidism 3
• Do NOT permanently abandon statins after first episode—92% of patients tolerate rechallenge 4
• Do NOT use coenzyme Q10—it is not recommended and lacks evidence for preventing or treating statin myalgias 1

The Zero Calcium Score Context

The zero coronary calcium score does not eliminate atherosclerotic risk in this patient 5. Recent evidence demonstrates:

• Noncalcified plaque can progress significantly despite CAC=0
• High-intensity statins slow noncalcified plaque progression even without baseline calcification
• Abdominal aortic atherosclerosis indicates systemic disease that warrants treatment regardless of coronary calcium

The presence of abdominal aortic atherosclerosis and psoriatic arthritis (both independent CV risk factors) justifies moderate-to-high intensity statin therapy despite zero coronary calcium 6, 7, 8.

Practical Expectations to Communicate

Tell your patient:

• Most likely scenario (80-95%): No muscle symptoms or mild transient aches that resolve
• If symptoms occur: Usually manageable with dose adjustment or statin switch
• Severe myopathy: Rare (<1% in trials) 1
• Rhabdomyolysis: Extremely rare

The cardiovascular mortality benefit in this high-risk patient substantially outweighs the small risk of manageable muscle symptoms.